RGNX GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Regenxbio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
Current Price
$5.72
-8.41%GoodMoat Value
$8.23
43.9% undervaluedProfile
Valuation (TTM)
Market Cap$295.23M
P/E-1.02
EV—
P/B2.87
Shares Out51.61M
P/Sales3.36
Revenue$87.82M
EV/EBITDA—
Regenxbio Inc (RGNX) Quality Analysis
RGNX Profitability
Profitability trend analysis coming soon
RGNX Growth
Growth trend analysis coming soon
RGNX Financial Health
Financial health indicators coming soon
RGNX Quality & Fundamental Analysis
Regenxbio Inc (RGNX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Regenxbio Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Regenxbio Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -330.23% and a return on equity (ROE) of -282.30%. Return on assets (ROA) stands at -64.02%.
The debt-to-equity ratio is 2.54, with a current ratio of 2.38. Operating margin is -94.58%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Regenxbio Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.